title: Is amisulpride safe when prescribed to breast and prostate cancer patients?
abstract: In the last decades, the potential association between antidepressants and cancer risk has been increasingly investigated. Fundamental researches, performed on animal models and cell tumoral lines, have highlighted several biological mechanisms possibly supporting this association. Nevertheless, the epidemiological studies investigating the risk of cancer in patients receiving selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) have provided conflicting and inconclusive results. Therefore, the prescription of several antidepressants in oncologic patients still remains a matter of discussion. The aim of this review is to present and discuss available evidence concerning the association between the risk of breast and prostate cancer and the use of antidepressant medications. Thus, consistencies, differences, and contradictions of available data are reported. A special focus is addressed to amisulpiride, a widely prescribed drug still poorly investigated with regard to the risk of cancer occurrence and recurrence. Overall, there is no definitive evidence of increased risk of breast and prostate cancer among patients exposed to SSRIs and TCAs. The association between amisulpiride and cancer risk has been to date scarcely explored and considered in clinical settings. Nevertheless, the hyperprolactinemia frequently resulting from its adoption has been repeatedly associated, to increased cancer risk and poorer prognosis in cancer patients. Thus, the use of amisulpiride among cancer patients should be carefully considered.
authors.affiliation: Department of Neurology and Psychiatry, Sapienza University of Rome, Italy; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Pasquini
authors.forename: I
authors.initials: I
authors.lastname: Berardelli
authors.forename: F
authors.initials: F
authors.lastname: Calabrò
authors.forename: V
authors.initials: V
authors.lastname: Roselli
authors.forename: S
authors.initials: S
authors.lastname: Hefner
authors.forename: M
authors.initials: M
authors.lastname: Biondi
mesh_terms: D000077582:Amisulpride; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000139:chemically induced / Q000453:epidemiology*; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000453:epidemiology / Q000378:metabolism; D008297:Male; D011471:Prostatic Neoplasms / Q000139:chemically induced / Q000453:epidemiology*; D018570:Risk Assessment; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D013469:Sulpiride; D000077582:Amisulpride